This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Beckman Research Institute, City of Hope. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Michael Barish: Innovator in Chimeric Antigen Receptors
Introduction
Michael Barish is a notable inventor based in Duarte, California. He has made significant contributions to the field of immunotherapy through his innovative work on chimeric antigen receptors (CARs). His research focuses on developing advanced therapeutic strategies for treating human tumors, particularly gliomas.
Latest Patents
Michael Barish holds a patent for "Chimeric antigen receptors containing a chlorotoxin domain." This patent describes chimeric transmembrane immunoreceptors that include an extracellular domain featuring chlorotoxin or a related toxin. These receptors are designed to bind to human glioma or other human tumor cells, incorporating a transmembrane region, a costimulatory domain, and an intracellular signaling domain.
Career Highlights
Barish is affiliated with City of Hope, a prominent research and treatment center. His work at this institution has been pivotal in advancing cancer therapies. He has dedicated his career to exploring innovative solutions that enhance the effectiveness of immunotherapy.
Collaborations
Michael Barish collaborates with esteemed colleagues, including Christine E. Brown and Stephen J. Forman. Their combined expertise contributes to the ongoing research and development of groundbreaking cancer treatments.
Conclusion
Michael Barish's contributions to the field of immunotherapy through his patent on chimeric antigen receptors highlight his role as an innovator in cancer treatment. His work continues to inspire advancements in therapeutic strategies for challenging tumors.